Typically, $100,000 to $150,000 per quality-adjusted life-year is accepted as cost-effective, but Avastin as a first-line treatment was associated with a $240,814 price tag per QALY. As a second-line treatment, Avastin cost $363,066 per QALY.
The drug may become cost-effective if a biomarker to identify the patients who would most benefit was discovered. Researchers have yet to identify such a biomarker.
More articles on gastroenterology:
Balloon colonoscope improves polyp detection
10 statistics on gastroenterologist salary by subspecialty
Gastroenterologists & ACOs: In or out?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
